Genmab — November 2020
-
God morgen.

-
Asien: Store forventninger giver pæne stigninger i hele regionen - NYhttps://www.proinvestor.com/investornyt/669406/asien-store-forventninger-giver-paene-stigninger-i-hele-regionen-ny
-
Mandagens aviser med FLSmidth, Tryg og Novo Nordiskhttps://www.proinvestor.com/investornyt/669412/mandagens-aviser-med-flsmidth-tryg-og-novo-nordisk
-
Godmorgen. Så er det GEN1046 dag. Har vi godt nok ventet længe på. Spændende...
-
Hvad tid kan vi forvente nyheder?
-
-
Ok. Tak skal du have Solsen

-
Aktier/tendens: Fokus på Novo og Vestas i marked i rekordhumør; https://www.proinvestor.com/investornyt/669418/aktier-tendens-fokus-pa-novo-og-vestas-i-marked-i-rekordhumor
-
EMA CHMP agenda this week: 5.1.3. Kyprolis - carfilzomib - Orphan -
Amgen Europe B.V. Scope: “Extension of existing indication to include combination of Kyprolis with
daratumumab and dexamethasone. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the
SmPC are updated. The package leaflet is updated in accordance.”
Action: For adoption
Request for Supplementary Information adopted on 28.05.2020.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind